Leaving patients to their own devices? Smart technology, safety and therapeutic relationships by Ho, Anita & Quick, Oliver
                          Ho, A., & Quick, O. (2018). Leaving patients to their own devices? Smart
technology, safety and therapeutic relationships. BMC Medical Ethics, 19,
[18]. https://doi.org/10.1186/s12910-018-0255-8
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1186/s12910-018-0255-8
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BioMed Central at
https://bmcmedethics.biomedcentral.com/articles/10.1186/s12910-018-0255-8. Please refer to any applicable
terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Ho and Quick BMC Medical Ethics  (2018) 19:18 
https://doi.org/10.1186/s12910-018-0255-8DEBATE Open AccessLeaving patients to their own devices?
Smart technology, safety and therapeutic
relationships
Anita Ho1,2,3* and Oliver Quick4Abstract
Background: This debate article explores how smart technologies may create a double-edged sword for patient
safety and effective therapeutic relationships. Increasing utilization of health monitoring devices by patients will
likely become an important aspect of self-care and preventive medicine. It may also help to enhance accurate
symptom reports, diagnoses, and prompt referral to specialist care where appropriate. However, the development,
marketing, and use of such technology raise significant ethical implications for therapeutic relationships and patient
safety.
Main text: Drawing on lessons learned from other direct-to-consumer health products such as genetic testing, this
article explores how smart technology can also pose regulatory challenges and encourage overutilization of
healthcare services. In order for smart technology to promote safer care and effective therapeutic encounters, the
technology and its utilization must be safe.
Conclusion: This article argues for unified regulatory guidelines and better education for both healthcare providers
and patients regarding the benefits and risks of these devices.
Keywords: Technology, Telemedicine, Patient safety, Medical ethics, Medical education, Professional regulation,
Patient engagementBackground
The use of technology in diagnosis and treatment is es-
sential to safe and effective health care, although it may
itself cause iatrogenic harm if not properly designed or
used [1]. This paper explores the ethical implications of
a specific type of information and communication tech-
nology on healthcare delivery: direct-to-consumer
(DTC) self-monitoring devices and smartphone apps.
Smart technology is now central to the vision of various
healthcare systems towards more personalised care de-
livery [2], and may be especially useful in the context of
an ageing population, an increasing prevalence of
chronic conditions, and the goal of keeping patients out
of hospitals. However, smart technologies may create a
double-edged sword for therapeutic relationships and* Correspondence: anitaho.ethics@gmail.com
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(http://creativecommons.org/publicdomain/zepatient safety. On the one hand, when used properly,
these technologies may promote safe and effective care
delivery by empowering patients to take charge of their
own health and promote efficient sharing of pertinent
health information. On the other hand, if not regulated
or incorporated appropriately into clinical care, smart
technologies can pose significant ethical and safety
concerns.
Patient safety and smart technologies
Patient safety research is now firmly established on pro-
fessional and political agendas across the world [3–6].
International studies estimate that between 8 to 12% of
hospital admissions are associated with an adverse event,
i.e., an unintended injury caused by medical manage-
ment, rather than by the disease process [7]. As Merry
and Brookbanks explain, an error occurs when someone
tries to do the right thing but ends up doing the wrong
thing [8]. Medication errors such as prescription of the
wrong drug or dosage and missed or delayed diagnosesle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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problems [7]. In recent years, the study of adverse events
and medical errors has evolved into a broader concern with
safety – a more expansive and somewhat nebulous term [9]
which presents considerable challenges in terms of meas-
urement [10] and regulation [11].
Adverse events and medical errors pose specific profes-
sional and bioethical implications regarding disclosure to
patients as well as general ethical concerns around how
modern healthcare is delivered and coordinated [12]. Ad-
vancing health technologies promise more cutting-edge
diagnostic and treatment tools. Nonetheless, they also
introduce new care and process complexities for multidis-
ciplinary professionals. Given the basic bioethical tenets of
beneficence and non-maleficence, finding reliable ways to
track and prevent missed diagnoses is an important fron-
tier for patient safety and health service research [13].
Connected to this are systematic failures around the com-
munication of test results: some countries such as the UK
rely on patients to chase up test results and to alert staff
of missing and delayed results [14].
Various educational and communication strategies
have been identified for improving diagnostic and pre-
scription accuracy as well as reporting errors [15]. Infor-
mation and e-communication technologies for
professionals, such as electronic health records and
computerized physician order entry, are already widely
used [16]. Nonetheless, as monitoring and diagnostic
technologies evolve in the age of person-centred care,
can the use of smart technology by patients enhance
both therapeutic relationships and patient safety? How
can health systems and regulators ensure the appropriate
marketing and use of such technology so that these de-
vices can promote safe and efficient care organisation
and delivery?
The use of technology by patients managing their
health is not new. Patients with chronic conditions such
as hypertension have long been able to purchase blood
pressure monitors, and those with diabetes routinely
carry out blood glucose tests. Other DTC tests can diag-
nose sexually transmitted infections [17, 18], detect
pregnancy complications such as Group B strep [19],
predict bowel cancer [20] and provide preliminary risk
assessments for genetic conditions. Diagnostic and treat-
ment algorithms, such as devices that can provide ECG
reports via phone adaptors, and computer algorithms
that can analyse photos of skin rashes and send sug-
gested diagnosis and treatment options to patients via e-
mail or SMS [21], are also increasingly available.
As smartphone and its associated technology continue
to advance, device companies are increasingly targeting
asymptomatic and pre-symptomatic populations, reach-
ing not only patients but also healthy consumers. Half of
the world’s adult population own a smartphone, and thisis predicted to increase to 80% by 2020 [22]. With a low
barrier to market entry, there are estimated to be over
100,000 mobile healthcare apps [23], including various
DTC wellness wearables that continuously track vital
signs or provide basic dietary and exercise activity infor-
mation to users.
Smart technology has the potential for promoting eth-
ical and effective care delivery in at least two ways. First,
beneficence, or the promotion of patient well-being, is
generally accepted as an important bioethical principle.
Traditionally, symptomatic patients have to take several
steps and rely exclusively on their physicians for direct
information regarding their health. Many pre-
symptomatic individuals do not know of their own sus-
ceptibility to various conditions and would have to wait
until they have fallen ill before receiving medical atten-
tion or advice. Further delay of information ensues if la-
boratory tests are ordered. Patients in the UK often have
to take the initiative to obtain their results [14], whereas
many American physicians adopt the “no news is good
news” approach and wait until they have received con-
cerning laboratory reports before making appointments
with their patients to discuss the findings [24]. Patients
in both systems who do not hear back often wonder
with anxiety whether their results are “normal” or
whether their physicians simply have not received the
reports. Worse yet, sometimes reports are missed and
patients who require follow-up investigations or treat-
ments are not notified [24, 25].
As health-tracking devices allow patients immediate
access to their health data, they may enhance efficient
and timely sharing of vital information to wider patient
populations as well as facilitate more informed clinical
counselling. Smart devices may help health professionals
and patients in rural and isolated areas to share and co-
ordinate recorded information that is traditionally un-
available to such communities, thereby promoting more
equitable access to health information and correspond-
ing management options. With smart devices, patients
can ask more relevant and timely questions based on the
recorded information, and physicians can confirm the
accuracy of patients’ reports of their symptoms accord-
ingly. Patients with busy lives or cognitive decline can
particularly benefit, as they may recall their symptoms,
activities, and other information incorrectly [26], espe-
cially when there is a significant time lapse between no-
ticing the symptoms and consulting a physician [27]. At
other times, patients’ physiological responses (e.g. heart
rate) may fluctuate depending on various circumstances
(e.g. work stress), such that their physiological markers
at the time of their clinical consultation may not tell the
full story. Having recorded information that spans a
period of time may provide clinicians a more complete
picture of the patient’s condition that can help to
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Second, the democratization of health information
may allow consumers to access information for disease
and illness prevention. More importantly, the direct
availability of health information to patients has the po-
tential of facilitating a more mutual therapeutic relation-
ship, where informed patients can be actively involved in
their care and treatment decisions [28]. By allowing pa-
tients and consumers to bypass traditional routes for
accessing certain health information, DTC smart tech-
nology can potentially empower consumers in their
everyday lives and patients in the care delivery process
respectively. In the realm of clinical care, the rhetoric of
patient- and family-centred care abound. Nonetheless,
the notions of expertise and legitimacy continue to affect
professionals’ willingness to take patients’ and families’
concerns seriously. As Coulter explains, patient expertise
is often dismissed as a ‘fluffy notion that lacks the solid
underpinning of scientific rigour on which medical care
is supposedly built’ [29]. The tendency to under-value
concerns expressed by patients and their caregivers can
be regarded as a form of testimonial injustice [30], where
too much or too little credibility is given to doctors’ or
patients’ words because of prejudices about their re-
spective roles. The utilization of smart monitoring tech-
nologies, especially if coupled with target counselling
and education by healthcare professionals [31], may in-
crease health literacy, empower patients to take a more
active and informed role in the management of their
own health, and bestow on patients more testimonial
credibility. Connecting to our aforementioned argument
from beneficence, if patients can present relevant and re-
liable data to validate their symptoms, they may be able
to obtain speedier and more accurate diagnoses, thereby
enhancing patient safety and well-being.
Patient safety and ethical concerns regarding self-
monitoring devices
While the increasing use of self-monitoring devices may
facilitate patient engagement in the care delivery
process, their value in promoting better health outcomes
will depend on at least three significant factors.
First, the integrity and clinical utility of information
from some DTC smart devices are currently question-
able. As we learn from criticisms of DTC genetic tests,
where individuals can send in cheek swabs to obtain
genetic information regarding their risk of developing
various conditions such as heart disease, diabetes, can-
cer, or Alzheimer’s, these test results may not be clinic-
ally meaningful or can be misinterpreted [32]. Medical
devices are regulated by agencies such as the Food and
Drug Administration (FDA) in the USA [33] and the
Medicines and Healthcare Products Regulatory Agency(MHRA) in the UK [34]. Products which claim to diag-
nose, treat or prevent disease (including software appli-
cations) are likely to be classified as devices and
regulated accordingly. Nonetheless, despite being aggres-
sively marketed as health-promoting tools, wellness
wearables which monitor general fitness are not formally
categorised as medical devices and are thus not regu-
lated. Limited studies exist regarding the accuracy or
validity of various “symptom checker” apps, which are
mostly developed by lay entrepreneurs rather than
healthcare professionals [23]. There is currently no
process of peer review beyond a simple anonymous user
rating scale [35], even though these products may still
present psychological and even physical risks to con-
sumers and patients if they do not work as intended
[36]. Such safety concerns raise questions of how regula-
tory and professional bodies should promote non-
maleficence and beneficence as per these devices. Since
some companies appeal to algorithmic authority to pro-
mote their apps to potential users [37] or purport to aid
patients to self-diagnose with minimal evidence base, the
potential for misuse is concerning [38]. Care providers
may also have trouble keeping up with these develop-
ments, making it challenging for them to educate or
warn patients accordingly. For example, the UK National
Health Service (NHS) launched a pilot health apps li-
brary in 2013 and currently lists fourty-three apps as
safe and trusted for patient use, raising questions about
the safety and utility of other DTC devices [39].
Second, while meaningful data that can confirm one’s
healthy status can reassure most patients, for the “wor-
ried well,” the device data may ironically exacerbate their
health anxiety and compromise patient safety rather
than promote productive engagement [40]. In the case
of genetic tests, information about having or not having
a particular gene mutation does not tell the whole story
about one’s susceptibility to various conditions. The
same applies to some biomarkers that need to be inter-
preted within the context of other variables. For ex-
ample, a heart tracing that looks unusual for an
asymptomatic person can be meaningless. However, in
the absence of comprehensive patient and consumer
education, healthy but anxious individuals may flock to
their physicians and seek additional testing upon am-
biguous results [41]. This can compromise therapeutic
relationships, patient safety, and appropriate allocation
of scarce medical resources. From over-prescription of
proton-pump inhibitors to near-universal use of
hormone-replacement therapy for postmenopausal
women [42, 43], iatrogenic health risks from over-
diagnosis and overtreatment abound [44]. The tide
against medical paternalism may discourage clinicians
from overtly dissuading consumers and patients from
using health-tracking devices. Nonetheless, in the name
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feel pressured to practice “defensive medicine” and order
further tests or low-value treatments that may carry other
risks in order to avoid possible litigation [45]. Transferring
the costs of follow-up testing and care from for-profit de-
vice companies to healthcare systems that are already
overstretched also incur wasteful spending and pose just-
ice considerations.
Third, by marketing directly to consumers, device com-
panies are shifting the delicate but important balance in
provider-patient relationships. If device users are primarily
consumers rather than patients, a “buyer-beware” attitude
may result, diminishing the importance of the therapeutic
relationship. As Entwistle [46] argues, efforts to ‘activate’
individual patients to use various devices in the name of
self-care “can be problematic if insufficient account is
taken of patients’ own agendas, learning skills, and mater-
ial and social circumstances.” An increasing expectation of
patients to be actively and technologically engaged in their
own care and an over-reliance on these applications re-
gardless of patients’ desire, technological literacy, and eco-
nomic means may violate patients’ autonomy and
exacerbate access disparity [47]. It may marginalize pa-
tients who have no affordable or reliable access to internet
or mobile technologies, such as people who live in rural
or isolated areas, and affect others who feel uncomfortable
with these technologies (e.g., elderly patients). Moreover,
reliance on information from monitoring devices may
ironically promote other forms of distrust. On the one
hand, smart devices may render patients’ own testimony
as being less credible, if their report cannot be supported
by corresponding “objective” data. These concerns are evi-
dent in the treatment of chronic pain, where the pathology
(e.g., lower back injury) does not always correspond to the
reported severity by the patient [48]. Some physicians may
thus question the truthfulness of the patient’s testimony
regarding their symptoms, thereby reducing pain manage-
ment ‘problems’ to doubts about patients’ trustworthiness
[49]. On the other hand, patients who receive professional
diagnoses that differ from what the devices suggest – es-
pecially for the aforementioned worried well – may dis-
trust their physicians and their therapeutic
recommendations. Under-treatment due to distrust of pa-
tients’ testimony and dismissal of professional advice
based on patients’ over-reliance on these devices can both
compromise therapeutic relationships and patient safety.
Conclusion
Smart technology has the potential to facilitate patient
engagement and strengthen the credibility of patient tes-
timony, which may in turn help to promote patient
safety and ethical therapeutic relationships. Nonetheless,
the reliability and clinical utility of many of these devices
have yet to be proven. There are also privacy and dataconfidentiality considerations that are beyond the scope
of this brief debate article. To maximize the potential of
these technologies, regulatory bodies need to develop
clear and unified guidelines in distinguishing “recre-
ational” from “medical” devices and monitor their mar-
keting claims and safety respectively. For example, the
utilization of a comprehensive risk assessment frame-
work can help regulatory agencies to evaluate the com-
plexity of an application and its probability and severity
of harm [50]. Some agencies, such as the aforemen-
tioned Food and Drug Administration in the US [33]
and the UK Medicines and Healthcare Products Regula-
tory Agency [34], are developing guidance on regulating
and monitoring the efficacy of mobile medical applica-
tions. Creating a global infrastructure for mobile medical
applications to provide common guidelines and serve as
a repository for shared resources may also help to
standardize safety requirements and promote evidence-
based practices for patients [32].
Whilst the safety of medical devices is monitored by
regulators, much of smart technology (e.g., wellness
wearables) would fall outside of formal regulation, either
because it is not classified as a medical device or because
of enforcement discretion. Promotion of safe and appro-
priate use of these devices requires a more collaborative
approach among different stakeholders. In particular, it
requires the active educational and supervisory involve-
ment of professional organisations and consumer/patient
user experience feedback. In promoting non-maleficence
and beneficence in the realm of smart technologies, pro-
fessional organisations and patient advocacy groups can
partner together to ensure that healthcare providers and
consumers/patients are educated about the appropriate
use and limits of these devices. Such collaboration may
offer a more effective way to gather feedback and pro-
mote patient safety than formal regulations. For ex-
ample, accredited continuing medical education training,
which is widely available for various clinical devices, can
be a model for educating clinicians regarding various
smart technologies. It is only when these tools are mar-
keted and utilised properly in the context of informed
and supportive therapeutic relationships that they can
effectively promote not only patient engagement, but
also patient safety.Abbreviations
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